Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Pune, India, July 19, 2022 (GLOBE NEWSWIRE) -- According to MarketStudyReport, worldwide stretcher chairs industry which stood at a valuation of USD 198.56 million in 2021, is anticipated to attain...
-
New York, United States, July 13, 2022 (GLOBE NEWSWIRE) -- Ophthalmic Devices Market is expected to be worth USD 83.1 billion by 2030, with a CAGR of 4.7%. The Global Market for Ophthalmic devices...
-
MINNEAPOLIS, June 29, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced the first patient has been enrolled in the company’s pivotal REVERSE-HF (Ultrafiltration Versus IV...
-
Study’s primary endpoint and key secondary endpoints were metStudy found event-free survival and overall survival superior after treosulfan compared to RIC busulfan, also found non-relapse mortality...
-
Redding, California, June 01, 2022 (GLOBE NEWSWIRE) -- According to a new market research report titled, ‘Wheat Protein Market by Type (Vital Wheat Gluten, Protein Isolates, Hydrolyzed Proteins,...
-
- First clinical data demonstrating potential of SAFEbody technology platform to create best-in-class therapeutics - - Additional data from ongoing ADG126 clinical program to be...
-
Regina, SK, May 26, 2022 (GLOBE NEWSWIRE) -- A new $19 million project by Protein Industries Canada and a consortium of companies will help Canadian farmers further improve their substantiality and...
-
LEXINGTON, Mass. and AMSTERDAM, May 24, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
-
All 23 treated patients are alive at 2.6-year median follow-up without evidence of malignant transformation Data representing largest cohort of infants with XSCID treated with gene therapy presented...
-
Positive Bylvay™ (odevixibat) global commercial launch in U.S., Germany and United Kingdom with Q1 2022 product revenue, net $4.7 million Phase 3 ASSERT study in Alagille syndrome fully enrolled,...